We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy and Safety of MiSight ® Contact Lenses in Reducing the Progression of Childhood Myopia.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01917110
Recruitment Status : Completed
First Posted : August 6, 2013
Last Update Posted : August 3, 2020
Sponsor:
Information provided by (Responsible Party):
Coopervision, Inc.

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The purpose of the study is to quantify the effectiveness of CooperVision MiSight® (omafilcon A) soft (hydrophilic) contact lens in slowing the rate of progression of juvenile-onset myopia.

Condition or disease Intervention/treatment Phase
Myopia Device: omafilcon A Device: Spectacle Not Applicable

Detailed Description:
Subjects in two parallel groups were randomized and assigned to either the study contact lens (omafilcon a) or single vision spectacles.
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 79 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Efficacy and Safety of MiSight ® Contact Lenses in Reducing the Progression of Childhood Myopia, Not Pathological, Aged 8-12 Years Randomized Clinical Trial.
Actual Study Start Date : September 13, 2013
Actual Primary Completion Date : June 16, 2016
Actual Study Completion Date : June 16, 2016

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: omafilcon A
Contact Lens Group
 Device: omafilcon A
Active Comparator: Spectacle Group
Prescription at Baseline
 Device: Spectacle


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Change in the spherical equivalent refractive error relative to baseline. [ Time Frame: Baseline, 1 week, 1 month, 6 months, 12 months, 18 months, 24 months ]
  2. Change in axial length relative to baseline. [ Time Frame: Baseline, 1 week, 1 month, 6 months, 12 months, 18 months, 24 months ]
  3. Measurement of corneal curvature (keratometry)relative to baseline. [ Time Frame: Baseline, 1 week, 1 month, 6 months, 12 months, 18 months, 24 months ]

Secondary Outcome Measures :
  1. Measurement of pupil diameter relative to baseline. [ Time Frame: Baseline, 1 week, 1 month, 6 months, 12 months, 18 months, 24 months ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   8 Years to 12 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Prior to being considered eligible to participate in this study, each subject MUST:

    1. Be between 8 and 12 years of age inclusive at the baseline examination.

    2. Have:

      1. read the Informed Assent,
      2. been given an explanation of the Informed Assent,
      3. indicated an understanding of the Informed Assent and
      4. signed the Informed Assent Form.

    3. Have their parent or legal guardian:

      1. read the Informed Consent,
      2. been given an explanation of the Informed Consent,
      3. indicated an understanding of the Informed Consent and
      4. signed the Informed Consent Form.
    4. Along with their parent or guardian, be capable of comprehending the nature of the study, and be willing and able to adhere to the instructions set forth in this protocol.
    5. Along with their parent or guardian, agree to maintain the visit schedule and be able to keep all appointments as specified in the study protocol for the duration of the study
    6. Agree to accept either the control or test lens as assigned by the randomisation scheme.
    7. Agree to wear the assigned contact lenses for the duration of the 2 year study and to inform the study investigator if this schedule is interrupted. (Wearing time may be modified by the study staff for health reasons.)
    8. Possess wearable and visually functional eyeglasses.
    9. Be in good general health, based on his/her and parent's/guardian's knowledge.
    10. Have best-corrected visual acuity by manifest refraction of +0.10 logMAR (20/25 Snellen equivalent) or better in each eye.

    11. Meet the following refractive criteria determined by cycloplegic autorefraction at baseline:

      1. Spherical Equivalent Refractive Error (SERE): between -0.75 and -4.00 D inclusive.
      2. Astigmatism: < -0.75 D
      3. Anisometropia: < 1.00D

Exclusion Criteria:

  • Subjects may not be considered eligible if ANY of the following apply:

    1. Subject has previously or recently worn soft or rigid gas permeable contact lenses, including orthokeratology lenses.
    2. Subject appears to exhibit poor personal hygiene (that in the investigator's opinion might prevent safe contact lens wear).
    3. Subject is currently or prior to this study has been an active participant in another clinical study.
    4. Parent / guardian or close relative is a member, of the office staff, including the investigator(s).
    5. Current or prior use of bifocals, progressive addition lenses, atropine, pirenzepine or ANY other myopia control treatment.
    6. Subject was born earlier than 30 weeks or weighed less than 1500g (3.3lb) at birth.
    7. Regular use of ocular medications (prescription or over-the-counter), artificial tears, or wetting agents.
    8. Current use of systemic medications which may significantly affect contact lens wear, tear film production, pupil size, accommodation or refractive state. Such as, but not limited to: long term use of nasal decongestants (for example, pseudoephedrine, phenylephrine), antihistamines (for example, chlorpheniramine, diphenhydramine), Prednisolone or Ritalin (methylphenidate).
    9. A known allergy to fluorescein, benoxinate, proparacaine or tropicamide.
    10. A history of corneal hypoesthesia (reduced corneal sensitivity), corneal ulcer, corneal infiltrates, ocular viral or fungal infections or other recurrent ocular infections.
    11. Strabismus by cover test at far (4 m) or near (40 cm) wearing distance correction.
    12. Known ocular or systemic disease such as, but not limited to: anterior uveitis or iritis, episcleritis or scleritis, glaucoma, Sjogren's syndrome, lupus erythematosus, scleroderma, or diabetes.
    13. Any ocular, systemic or neuro-developmental conditions that could influence refractive development. Such as, but not limited to: persistent pupillary membrane, vitreous hemorrhage, cataract, corneal scarring, ptosis eyelid hemangiomas, Marfan's Syndrome, Down's syndrome, Ehler's-Danlos syndrome, Stickler's syndrome, ocular albinism, retinopathy of prematurity.
    14. Keratoconus or an irregular cornea.

    15. Biomicroscope findings that would contraindicate contact lens wear including, but not limited to:

      1. corneal scars within the visual axis
      2. neovascularisation or ghost vessels > 1.5 mm in from the limbus
      3. Any active anterior segment ocular disease that would contraindicate contact lens wear.
      4. giant papillary conjunctivitis of Grade 2 or worse
      5. allergic or seasonal conjunctivitis (if the study investigator believes it could significantly interfere with maintaining the specified contact lens wearing schedule)
      6. clinically significant (Grade 3 or 4) abnormalities of the anterior segment, lids, conjunctiva, sclera or associated structures.
    16. The investigator for any reason considers that it is not in the best interest of the subject to participate in the study.
    17. Have pathological myopia To be eligible to begin the study, a subject must have ALL of the inclusion criteria and NONE of the exclusion criteria present.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01917110


Locations
Layout table for location information
Spain
Departamento de Óptica y Optometría de la Universidad Europea de Madrid
Madrid, Spain
Sponsors and Collaborators
Coopervision, Inc.
Investigators
Layout table for investigator information
Principal Investigator: Cesar Villa Collar, OD PhD FAAO Departamento de Optica y Optometria de la Universidad Europea de Madrid
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
Responsible Party: Coopervision, Inc.
ClinicalTrials.gov Identifier: NCT01917110    
Other Study ID Numbers: P2013/05
First Posted: August 6, 2013    Key Record Dates
Last Update Posted: August 3, 2020
Last Verified: July 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Myopia
Refractive Errors
Eye Diseases